Biocon’s fundraising is viewed positively to manage debt. Expert Nischal Maheshwari is optimistic about Biocon’s future, expecting earlier investments to yield returns. He also favors contract development and manufacturing firms like Laurus Labs. Maheshwari sees potential in banking, metals, and power sectors, particularly execution-focused players in power.
12 equity mutual funds with over Rs 1,000 NAV offer upto 24% CAGR since their inception. Do you own any?
Out of these 12 funds, 11 have been in the market for more than 25 years. They have delivered consistent double-digit returns over decades, highlighting